Critical review on Haritaki w.s.r. to Sthaulya (obesity)
Abstract
Obesity is a major risk factor for a number of chronic diseases, including Diabetes, Cardiovascular disease & Cancer etc. In 2013, the American Medical Association (AMA) declared Obesity a disease that requires a range of interventions to advance treatment & prevention. So, it is the need of the hour to develop better treatment protocol to treat & prevent the condition. Ayurveda has the potential in the prevention, management & improvement of the quality of life in obese patient. Haritaki having properties like Kaphaghna, Medoghna, Deepana, Pachana, Ruksha, Laghu Guna, Katu, Tikta Rasa and Ushna Veerya, it does the Sthaulya Samprapti Vighatana. Various studies also suggested that Haritaki possesses an antiobesity and hypolipidemic effects based on Kaphanashak and Medoghna properties and presence of its biologically active components like saponins, phytosterols, chebulinic acid and corilagin. Therefore, Haritaki can be useful as an adjuvant therapy for Obesity.
Downloads
References
Singh Rajani, Rath Sudipta Kumar. Review of Haritaki (tTrminalia Chebularetz.) as an ekal dravya chikitsa in Brihatrayee. Int J Ayu Pharm Res [Internet]. 2021Feb.9 [cited 2021 Jul.20];9(1):33-0. Available from: https://ijapr.in/index.php/ijapr/article/view/1762
Medscape.Is Obesity a Disease or a Choice? 2018 July 05. [last cited 14 February 2019]. Available from: https://www.medscape.com/viewarticle/898921
Chunekar. K.C, Bhavaprakasha nighantu of Bhavamishra.Varanasi:Choukhamba Bharati Academy. Reprint Edition 2020: P.3
Chunekar. K.C, Bhavaprakasha nighantu of Bhavamishra. Varanasi:Choukhamba Bharati Academy. Reprint Edition 2020: P.3
Sharma P.V., Dravyaguna Vijyana, Vol.- II, Varanasi:Chaukhambha Bharti Academy ; E 2006. P.753
Chunekar. K.C, Bhavaprakasha nighantu of Bhavamishra. Varanasi:Choukhamba Bharati Academy. Reprint Edition 2020: P.5
Chunekar. K.C, Bhavaprakasha nighantu of Bhavamishra. Varanasi:Choukhamba Bharati Academy. Reprint Edition 2020: P.13
Meher Sudhanshu et.al. Pharmacological Profile of Terminalia chebula Retz. and Willd. (Haritaki) in Ayurveda with Evidences. RJPPD.2018; 10(3):115-124.
Gupta A. et.al. Phytochemistry and Pharmacological activities of Haritaki – A review. J. Pharm. Res. 2010;3(2):417–424.
W. Lee, S. Y. Lee, Y. Son, and J. Yun, “Gallic acid decreases inflammatory cytokine secretion through histone acetyltransferase/histone deacetylase regulation in high glucose-induced human monocytes,” Journal of Medicinal Food.2015 ;18(7):793–801
Upadhyay Aparna et.al. A Review on the Pharmacological Aspects of Terminalia chebula. IJP.2014; 10: 289-298
Upadhyay Aparna et.al. A Review on the Pharmacological Aspects of Terminalia chebula. IJP.2014; 10: 289-298
Ahn MJ et.al. Inhibition of HIV-1 integrase by galloyl glucoses from Terminalia chebula and flavonol glycoside gallates from Euphorbia pekinensis. Planta Med. 2002 May; 68 (5):457-9
Assie Jokar et.al. Potential therapeutic applications for Terminalia chebula in Iranian traditional medicine. JTCM.2016;36,(2): 250-254
Assie Jokar et.al. Potential therapeutic applications for Terminalia chebula in Iranian traditional medicine. JTCM.2016;36,(2): 250-254
WHO. Obesity & overweight. 2018 February16. [last cited 14 February 2019]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Shashtri Kashinath. Charak Samhita of Agnivesha.Sutra Sthana. Ch.21, Vers 4. Vol. 1. Vidhyotini Hindi Commentary.Varanasi: Chaukhambha BhartiAcademy; 2017. P. 409
Copyright (c) 2022 Shilky Patel, Nitin Marwaha, Charu Bansal, Trupti Jain
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Ayurveda and Integrated Medical Sciences (JAIMS) retains the copyright of the contents of this journal but grant the readers the right to use the contents with terms and conditions under a creative common attribution licenses 4 of Attribution, Share Alike and Non-commercial type (CC BY-NC-SA) that allows copy, distribute, display, and perform the work and make derivative works based on it only for non-commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.